AzTrials
AzTrials

COPD Patients and Patients Recovering From COVID19NCT03655028

Increasing Physical Activity in COPD Through Rhythmically Enhanced Music

A study testing rhythmically auditory stimulation enhanced music in people with COPD Patients and Patients Recovering From COVID19, run by VA Office of Research and Development at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The VA cares for nearly one million Veterans with COPD at a cost of more than $5.5 billion annually. COPD profoundly impairs quality of life as it limits ability to work, to maintain physical exertion and to engage in social activities. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
rhythmically auditory stimulation enhanced music
Could I receive a placebo?
No, everyone receives an active treatment
How many people
93 participants
Where
1 siteUnited States
Study dates
1 Oct 2018to 14 Nov 2023
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • COPD patients:
  • =< 40 yr. of age
  • FEV1 =< 70%
  • FEV1/FVC <70%
  • Mean SpO2 88% at peak exercise (with or without oxygen supplementation)
  • COVID19 patients
Show all 11Show fewer
  • >=18 yrs. of age
  • Previous hospital and/or emergency room visit for laboratory-confirmed COVID-19 diagnosis.
  • Able to walk independently
  • Mean SpO2 88% at peak exercise (with or without oxygen supplementation)
  • Ability to hear music

Who cannot join

  • COPD patients:
  • Respiratory infection/COPD exacerbation within the previous four weeks
  • Exercise-limiting heart disease
  • Congestive heart failure - i.e., New York Heart Association Class III or IV
  • Positive stress test or other indicators of heart disease or complaints of angina during the stress test
  • Exercise-limiting peripheral arterial disease
Show all 19Show fewer
  • Stops walking due to intermittent claudication
  • Stops exercise for arthritic pain in knee or hips
  • Inability to walk on the treadmill
  • Any unforeseen illness or disability that would preclude exercise testing or training
  • Participation in a formal exercise program within the previous 12-weeks
  • COVID patients:
  • Able to walk more than 550 meters during a standard 6-minute walk test
  • Exercise limiting heart disease
  • Complaints of angina during the 6- minute walk distance tests or other indicators of exercise-limiting heart disease
  • Congestive heart failure (New York Heart Association Class III or IV)
  • Exercise-limiting peripheral arterial disease (stops exercise due to intermittent claudication)
  • Stops exercise due to arthritic pain in the knee or hips (self-report)
  • Pregnancy

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Edward Hines Jr. VA Hospital, Hines, IL

    Hines, Illinois, 60141-3030

Other trials in United States

About this study

The VA cares for nearly one million Veterans with COPD at a cost of more than $5.5 billion annually. COPD profoundly impairs quality of life as it limits ability to work, to maintain physical exertion and to engage in social activities. Hospital-based rehab can decrease the need for inpatient and outpatient medical care and can improve exercise capacity, quality of life and, possibly, decrease mortality. Unfortunately, access to hospital-based VA rehab is insufficient and, over time, the few Veterans who attend experience progressive loss of functional gains. The investigators reason that the proposed home-based exercise program augmented by patient-tailored, RAS-enhanced music will overcome the many limitations of hospital-based rehab. Through this innovative program, the investigators expect to enhance the benefits of rehab and better maintain them over time. The easy applicability of this innovative, accessible and economical program has the potential to modify the spiraling pattern of increasing disability and reduce health-care cost and mortality in Veterans with COPD.

In 2021, the investigators obtained an 'Administrative Project Modification' to the parent COPD study in which they will include patients recovering from prolonged COVID19 hospitalization. Specifically, the investigators will use the novel RAS-enhanced music exercise program developed for the parent grant in patients recovering from COVID19. The main goal of the modified proposal for COVID19 patients will be to compare the efficacy of a 12-week, home-based exercise program augmented by RAS-therapeutic music and strength training to 12-weeks usual care and strength training in patients recovering from COVID 19.

Read the detailed description

Rationale: In COPD, hospital-based pulmonary rehabilitation can improve symptoms, functional status, and quality of life and decrease unscheduled physician visits, emergency room visits, hospitalizations, and possibly, mortality. Despite the well documented efficacy, hospital-based rehab remains inadequate due to insufficient access, acceptance and sustainability. This has triggered a growing interest in home-based rehab programs. Patients enrolled in home-based programs, however, may exercise at low intensities to avoid dyspnea/fatigue, limiting the potential benefits of exercise training. Accordingly, it is essential to develop innovative home-based programs that decrease exercise-induced dyspnea and fatigue while ensuring sufficient exercise intensity to produce sustainable physiologic benefit. Recent data suggest that rhythmically auditory stimulation (RAS) using music may constitute such an innovative strategy. Music can diminish exercise-induced dyspnea/fatigue allowing patients to tolerate more challenging physical activity and obtain a greater benefit from rehab. Music also can induce entrainment of motor responses such as walking. The investigators thus plan to capitalize on both the sensorimotor coupling of gait with RAS-enhanced music and the mitigating effect of music over exercise-induced dyspnea/fatigue. Specifically, the investigators propose to compare the efficacy of a 12-week, home-based exercise program augmented by patient-tailored, RAS-enhanced music to a 12-week traditional home-based exercise program in patients with COPD. Hypothesis: (H1) Compared to patients randomized to a home-based, exercise program without music (control group), patients randomized to a home-based, exercise program augmented with RAS-enhanced music (intervention group) will demonstrate (H1a, primary hypothesis) greater increase in 6-minute walk distance, (H1b) greater increase in walking time on a constant-load treadmill test protocol, (H1c) reduced dyspnea during a constant-load treadmill test protocol, and (H1d) greater increases in health-related quality of life. In addition (H2), they will accumulate greater volume of physical activity (actigraphy) and (H3) will better sustain these benefits over time. Lastly (Explorative Objective), the investigators will assess the mechanistic impact physiological and psychological phenotype and clinical factors on responsiveness to rehabilitation (duration constant-load treadmill test) achieved with and without concurrent use of RAS-music. Methods: The proposed study is a randomized, controlled clinical trial in which 170 patients will be randomized into a home-based, exercise program without music or a home-based exercise program augmented with RAS-enhanced music. Patients will receive 12-weeks of home-based training per group assignment (at least three times weekly) followed by 12-weeks of follow-up to assess the sustainability of the investigators' novel intervention. Testing will be carried out at baseline and at 6, 12 and 24 weeks. Testing will include pulmonary function test, 6-minute walk tests, constant-load treadmill test, physical activity quantification, measurements of dyspnea, quality of life, and objective quantification of quadriceps dimensions (ultrasonography) and strength/fatigue (magnetic stimulation of the femoral nerve). Analysis: In the principal analysis of the primary outcome measure (6-minute walk distance) the investigators will use a mixed-model analysis that includes, treatment, time and treatment-by-time interaction terms. This model will automatically account for missing data-where missing at random is assumed. The investigators will conduct a sensitivity analysis based on the results of the mixed model analysis to determine which other assumptions regarding missing data might produce different results. One component of the sensitivity analysis will include adjustment for baseline demographic and health covariates. A linear regression model and a mixed model ANOVA will be used to assess the impact of clinical confounders (Explorative Objective). Scientific contribution: These data will provide a solid foundation to determine the physiologic impact of the rehab strategy. This innovative, practical and economical pulmonary rehabilitation strategy has the potential to create a paradigm shift in the care of the many Veterans with COPD who have no access to pulmonary rehabilitation. The above-described protocol will be also tested in patients recovering form COVID19. The investigators reason that the proposed innovative, practical, safe and economical program has the potential to create a paradigm shift in the care of the many veterans who were hospitalized with COVID19 and who have no access to physical rehabilitation.

Please note: Due to the COVID-19 pandemic, constant load treadmill testing could not be completed as was originally proposed. There was concern that COVID-19 could be transmitted due to increased exposure to increased saliva associated with testing. Therefore, the objectives using constant load testing will not be reported. The exploratory objective was based on the constant workload treadmill test so that is not reported. Additionally, again due to the COVID-19 pandemic, 6-week testing was not completed after the pandemic due to the increased risk of transmission (n.b., 6-week data were not included in the outcomes and was to be used for analysis of the primary objective; as such, the analysis of the primary objective was changed to ANCOVA from what was in the protocol). The protocol attached here is the last approved IRB protocol and includes both patients with COPD and COVID. Only data on patients with COPD are reported here. The two groups of patients were two different populations and it does not make theoretical sense to combine the data at this point. Text concerning COVID are in gray.

Being tested
rhythmically auditory stimulation enhanced music, control
Keywords
COPD, Exercise, Rehabilitation
Medical subject headings
Pulmonary Disease, Chronic Obstructive, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • rhythmically auditory stimulation enhanced musicBehavioural

    Patients in the intervention group will listen to music enhanced by rhythmic auditory stimulation while engaging in a 12-week home-based exercise program

  • controlBehavioural

    Patients in the control group will not listen to music while engaging in a 12-week home-based exercise program

Study groups in NCT03655028
Study groupRoleWhat they receive
RAS-music groupExperimentalHome-based, exercise program augmented with rhythmically auditory stimulation enhanced music
Receives: Behavioral: rhythmically auditory stimulation enhanced music
Control groupActive comparatorHome-based, exercise program without rhythmically auditory stimulation enhanced music
Receives: Behavioral: control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Six-minute Walk Distance

    Patients will be instructed to walk as fast as they can without running for six minutes. The test will be conducted according to ATS standards. Distance will be recorded in meters walked. Outcomes will be compared between the intervention groups.

    Measured: 12 weeks

Secondary outcomes (4)
  1. Volume of Daily Physical Activity

    Volume of daily physical activity over a seven day period will be recorded using a triaxial accelerometer worn on the hip (actigraph). Volume of physical activity will be compared between the intervention group and the control group.

    Measured: 12 weeks

  2. Six-minute Walk Distance

    To determine whether, 24-weeks after randomization, gains in 6-minute walk distance and perceived functional improvements will be sustained to a greater extent in the rhythmic auditory stimulation enhanced music group than in the control group the six-minutes walk test will be repeated 24-weeks after randomization. During the six-minute walk test patients will be instructed to walk as fast as they can without running for six minutes. The test will be conducted according to ATS standards. Distance will be recorded in meters walked. Outcomes will be compared between the two groups.

    Measured: 24 weeks

  3. Quality of Life Physical Function

    measured by the Short Form-36 Physical component score. Scores range from 0-100 (higher scores are better).

    Measured: 12 weeks

  4. Quality of Life Mental Health

    Quality of Life measured by Short Form-36 Mental Component Scale (range=0-100; higher score is better)

    Measured: 12-weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Aug 2018
  2. Study start1 Oct 2018
  3. Primary completion11 Sep 2023
  4. Study completion14 Nov 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomized controlled trial in which COPD patients in the intervention group and COVID19 patient in the intervention group will undergo a home-based, exercise program augmented with RAS-enhanced music while COPD patients in the control group and COVID19 patients in the control group will undergo a home-based, exercise program without music. Outcomes of the home-based exercise program with music will be compared to the outcomes of home-based exercise alone. Outcomes are listed below.
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
93 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03655028
Sponsor's protocol ID
E2803-R
Status last verified
Mar 2025
First submitted
29 Aug 2018
Last updated
17 Mar 2025
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing rhythmically auditory stimulation enhanced music in people with COPD Patients and Patients Recovering From COVID19, run by VA Office of Research and Development at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Mar 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Six-minute Walk Distance (time frame: 12 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in